KRAS and carcinoma: Additionally, although recent evidence has reported a role for overexpression of wild-type KRAS, HRAS, or NRAS in different carcinomas [51, 52], including invasive breast cancers [53], a driver role in their wild-type form for tumorigenesis in in vivo models has not yet been demonstrated.